• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[外源性肺表面活性物质替代治疗新生儿呼吸窘迫综合征过程中的体循环和肺循环血流动力学]

[Systemic and pulmonary hemodynamics in the course of substitute therapy with exosurf neonatal in newborn infants with respiratory distress syndrome].

作者信息

Milenin O B, Efimov M S

出版信息

Anesteziol Reanimatol. 1996 Nov-Dec(6):7-10.

PMID:9045592
Abstract

The effect of double endotracheal administration of Exosurf Neonatal (Wellcome, Great Britain) in a dose of 5 ml/kg on the central and pulmonary hemodynamics, frequency of hemodynamically significant functioning arterial duct (FAD), and lung hemorrhages was studied by Doppler echocardiography in 25 newborns with the respiratory distress syndrome. The hemodynamic parameters were assessed before drug administration, directly and 2 hours after it, and at the age of 1, 2, and 3 days. An unreliable reduction of pulmonary vascular resistance and increase of volumic pulmonary blood flow were observed as soon as during the first minutes after administration of exosurf; this was not paralleled by a pathological increase of the left-right shunting of the blood through patent ductus arteriosus. During the three days that followed the postloading of the right ventricle reliably decreased and the pulmonary bloodflow, cardiac output, and systemic arterial pressure increased. If the traditional measures preventing the possible volumic overloading of the pulmonary circulation in the presence of patent ductus arteriosus were not neglected, administration of exosurf to newborns with the respiratory distress syndrome did not lead to an increase in the frequency of hemodynamically significant FAD and pulmonary hemorrhages.

摘要

采用多普勒超声心动图,对25例患有呼吸窘迫综合征的新生儿进行研究,观察经气管内给予剂量为5ml/kg的固尔苏(英国威康公司)对其中心和肺血流动力学、血流动力学显著的功能性动脉导管(FAD)频率及肺出血的影响。于给药前、给药即刻及给药后2小时,以及出生后1、2和3天评估血流动力学参数。给药后最初几分钟内,即观察到肺血管阻力不可靠地降低,肺血容量增加;但通过动脉导管未闭的血液左右分流无病理性增加。在随后三天中,右心室后负荷可靠降低,肺血流量、心输出量及体动脉压增加。若不忽视预防动脉导管未闭时肺循环可能出现容量超负荷的传统措施,则给患有呼吸窘迫综合征的新生儿使用固尔苏不会导致血流动力学显著的FAD频率及肺出血增加。

相似文献

1
[Systemic and pulmonary hemodynamics in the course of substitute therapy with exosurf neonatal in newborn infants with respiratory distress syndrome].[外源性肺表面活性物质替代治疗新生儿呼吸窘迫综合征过程中的体循环和肺循环血流动力学]
Anesteziol Reanimatol. 1996 Nov-Dec(6):7-10.
2
[Use of Exosurf Neonatal, a synthetic surfactant, in the treatment of respiratory distress syndrome in the newborn].
Anesteziol Reanimatol. 1995 Jan-Feb(1):4-7.
3
A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.一项关于合成表面活性剂与小牛肺表面活性剂提取物预防新生儿呼吸窘迫综合征的多中心随机双盲对照试验。
Pediatrics. 1997 Jul;100(1):39-50. doi: 10.1542/peds.100.1.39.
4
Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant.单剂量合成表面活性剂治疗的极低出生体重儿在28日龄时预后改善。
J Pediatr. 1990 Dec;117(6):947-53. doi: 10.1016/s0022-3476(05)80143-x.
5
Criteria for use of colfosceril (Exosurf) in neonates.
Clin Pharm. 1992 Apr;11(4):355-7.
6
A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.一项比较两种表面活性剂治疗新生儿呼吸窘迫综合征的多中心随机试验。国家儿童健康与人类发展研究所新生儿研究网络。
J Pediatr. 1993 Nov;123(5):757-66. doi: 10.1016/s0022-3476(05)80856-x.
7
A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.一项针对体重1250克及以上患有呼吸窘迫综合征婴儿的合成表面活性剂对照试验。美国外源性表面活性物质新生儿研究组I和加拿大外源性表面活性物质新生儿研究组。
N Engl J Med. 1991 Dec 12;325(24):1696-703. doi: 10.1056/NEJM199112123252404.
8
Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.棕榈酸考福斯昔尔。合成表面活性剂制剂(固尔苏)治疗新生儿呼吸窘迫综合征的疗效及临床耐受性综述。
Drugs. 1991 Nov;42(5):877-94. doi: 10.2165/00003495-199142050-00009.
9
Exosurf treatment investigational new drug phase: effect of an individualized third dose in infants with respiratory distress syndrome.外源性表面活性物质治疗研究性新药阶段:个体化第三剂对呼吸窘迫综合征婴儿的影响。
Pediatr Pulmonol. 1992 Sep;14(1):16-22. doi: 10.1002/ppul.1950140105.
10
Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country.人工合成与天然表面活性剂治疗早产儿呼吸窘迫综合征的对比试验:发展中国家的经验
Pediatr Pulmonol. 1999 May;27(5):312-7. doi: 10.1002/(sici)1099-0496(199905)27:5<312::aid-ppul3>3.0.co;2-n.